AMD Pharmacogenetics

Vita Risk Pharmacogenetic Result

The Vita Risk pharmacogenetic result within the Macula Risk PGx test is intended to support the genotype-directed selection of appropriate eye vitamin formulations. The eye vitamin formulation (AREDS, antioxidants alone, or zinc alone) shown to result in the greatest reduction in the risk of progression to advanced AMD for the patient’s combined CFH/ARMS2 genotype is recommended [10].
The Vita Risk pharmacogenetic result is covered by US Patent application number: 13/955502


The Vita Risk Patient Report is shown below: